Toripalimab

Generic Name
Toripalimab
Brand Names
Loqtorzi
Drug Type
Biotech
Chemical Formula
-
CAS Number
1924598-82-2
Unique Ingredient Identifier
8JXN261VVA
Background

Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication

⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌(NPC)。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌(UC)。⑷用于食管鳞癌一线治疗。

Associated Conditions
-
Associated Therapies
-

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-10-02
Last Posted Date
2024-10-02
Lead Sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Target Recruit Count
40
Registration Number
NCT06623136
Locations
🇨🇳

Jilin Cancer Hospital, Changchun, Jilin, China

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

First Posted Date
2024-10-01
Last Posted Date
2024-12-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT06618014
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

First Posted Date
2024-09-25
Last Posted Date
2024-09-25
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
100
Registration Number
NCT06612632
Locations
🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

First Posted Date
2024-09-12
Last Posted Date
2024-09-12
Lead Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Target Recruit Count
460
Registration Number
NCT06592326
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

First Posted Date
2024-09-12
Last Posted Date
2024-09-12
Lead Sponsor
Stanford University
Target Recruit Count
24
Registration Number
NCT06592599
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer

Early Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-11-01
Lead Sponsor
Ruijin Hospital
Target Recruit Count
56
Registration Number
NCT06577532
Locations
🇨🇳

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-08-12
Last Posted Date
2024-08-12
Lead Sponsor
Fudan University
Target Recruit Count
30
Registration Number
NCT06548763
Locations
🇨🇳

Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
34
Registration Number
NCT06547203
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath